CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and morta...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-10, Vol.25 (19), p.10511
Main Authors: Abdalhadi, Haneen M, Chatham, Walter W, Alduraibi, Fatima K
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antigens
Arthritis
Autoimmune diseases
B cells
CAR-T-cell therapy
Cells
Clinical trials
Cytotoxicity
Disease
Drug therapy
Federal regulation
Humans
Immune system
Immunotherapy, Adoptive - methods
Ligands
Lupus
Lupus Erythematosus, Systemic - immunology
Lupus Erythematosus, Systemic - therapy
Medical prognosis
Medical research
Pathogenesis
Receptors, Chimeric Antigen - immunology
Receptors, Chimeric Antigen - metabolism
Remission (Medicine)
Review
Systemic lupus erythematosus
T-Lymphocytes - immunology
T-Lymphocytes - metabolism
Transplants & implants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and mortality. Given its complex pathogenesis, conventional treatments for SLE often have significant side effects and limited efficacy, necessitating the exploration of novel therapeutic strategies. One promising approach is the use of chimeric antigen receptor (CAR)-T-cell therapy, which has shown remarkable success in treating refractory hematological malignancies. This review provides a comprehensive analysis of the current use of CAR-T-cell therapy in SLE.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms251910511